Cargando…
Non-anti TNF biologic modifier drugs in non-infectious refractory chronic uveitis: the current evidence from a systematic review
Autores principales: | Simonini, Gabriele, Cimaz, Rolando, Jones, Gareth T, Macfarlane, Gary J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190916/ http://dx.doi.org/10.1186/1546-0096-12-S1-P120 |
Ejemplares similares
-
PReS-FINAL-2347: Does switching anti-TNFΑ biologic agents an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach
por: Simonini, G, et al.
Publicado: (2013) -
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
por: Simonini, Gabriele, et al.
Publicado: (2013) -
Current evidence of MTX efficacy in childhood chronic uveitis: a systematic review and meta-analysis
por: Simonini, G, et al.
Publicado: (2011) -
PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013) -
PReS-FINAL-2211: NOD2/CARD15 polymorphisms and clinical features in patients with non-infectious uveitis
por: Marrani, E, et al.
Publicado: (2013)